Abstract
Background and Aims : Statins are effective for lipid lowering, but some statins increase risk for early onset of type 2 diabetes (T2D). Continuing reports with this conclusion have led to uncertainty among clinicians about discontinuing or limiting statin therapy. In this study, we extended our β-cell studies to further elucidate differences between simvastatin (SVA) and pitavastatin (PVA) based on quantitative measurements of glucose-induced insulin secretion (GSIS).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
